MXPA05011410A - Tratamiento de incontinencia con agonistas de 5htc2. - Google Patents

Tratamiento de incontinencia con agonistas de 5htc2.

Info

Publication number
MXPA05011410A
MXPA05011410A MXPA05011410A MXPA05011410A MXPA05011410A MX PA05011410 A MXPA05011410 A MX PA05011410A MX PA05011410 A MXPA05011410 A MX PA05011410A MX PA05011410 A MXPA05011410 A MX PA05011410A MX PA05011410 A MXPA05011410 A MX PA05011410A
Authority
MX
Mexico
Prior art keywords
treatment
incontinence
agonists
5htc2
relates
Prior art date
Application number
MXPA05011410A
Other languages
English (en)
Inventor
Wesley Dennis Miner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33397006&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05011410(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA05011410A publication Critical patent/MXPA05011410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere al uso de agonistas de receptores 5HT2C para el tratamiento de la incontinencia urinaria, preferiblemente incontinencia mixta o incontinencia urinaria provocada por estres; la invencion se refiere tambien al uso de antagonistas de receptores 5HT2C para el tratamiento de la retencion urinaria; la presente invencion se refiere tambien a un procedimiento de tratamiento de la incontinencia, a ensayos para seleccionar compuestos utiles en el tratamiento de la incontinencia y a procedimientos para preparar composiciones para el tratamiento de incontinencia urinaria.
MXPA05011410A 2003-04-25 2004-04-21 Tratamiento de incontinencia con agonistas de 5htc2. MXPA05011410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0309533 2003-04-25
PCT/IB2004/001437 WO2004096196A2 (en) 2003-04-25 2004-04-21 Treatment of incontinence with 5htc2 agonists

Publications (1)

Publication Number Publication Date
MXPA05011410A true MXPA05011410A (es) 2005-12-12

Family

ID=33397006

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011410A MXPA05011410A (es) 2003-04-25 2004-04-21 Tratamiento de incontinencia con agonistas de 5htc2.

Country Status (13)

Country Link
EP (2) EP2277513A3 (es)
JP (2) JP2006524679A (es)
KR (3) KR20060006063A (es)
CN (1) CN1780612B (es)
AU (2) AU2004233745B2 (es)
BR (1) BRPI0409730A (es)
CA (2) CA2670067A1 (es)
CL (1) CL2004000826A1 (es)
MX (1) MXPA05011410A (es)
MY (1) MY142857A (es)
TW (1) TW200426142A (es)
WO (1) WO2004096196A2 (es)
ZA (1) ZA200507158B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
WO2006116169A2 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
US20080234280A1 (en) * 2005-08-01 2008-09-25 Mcmurray Gordon Use of Mc4 Receptor Agonist Compounds
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
JPWO2008007664A1 (ja) 2006-07-11 2009-12-10 武田薬品工業株式会社 二環性複素環化合物およびその用途
JP5497429B2 (ja) 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2009063993A1 (ja) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
JP5361733B2 (ja) 2007-11-15 2013-12-04 武田薬品工業株式会社 ピリドオキサゼピン誘導体およびその用途
MY157497A (en) 2009-06-15 2016-06-15 Takeda Pharmaceutical Pyrazinooxazepine derivatives
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
WO2012002583A1 (en) * 2010-07-02 2012-01-05 Vanderbilt University Method for treating schizophrenia and related diseases with a combination therapy
EP2824106B1 (en) 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
CA2044854A1 (en) 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW270114B (es) 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
AU5343298A (en) 1997-01-13 1998-08-03 Yamanouchi Pharmaceutical Co., Ltd. 5-ht2c receptor agonists and aminoalkylindazole derivatives
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
ES2208812T3 (es) 1997-02-25 2004-06-16 Akzo Nobel N.V. Derivados de azetidina y de pirrolidina.
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU727654B2 (en) 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
NZ506465A (en) * 1998-02-26 2003-08-29 Akzo Nobel Nv Derivatives of azetidine and pyrrolidine
AU4037699A (en) 1998-05-08 1999-11-29 Akzo Nobel N.V. Novel aryl-hydro naphthalenal kanamines
GB9819020D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds III
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819019D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9819032D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds IV
GB9820767D0 (en) 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
SK8192001A3 (en) 1998-12-17 2001-12-03 American Home Prod 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivatives being 5ht2c agonists
CA2361516A1 (en) 1999-01-27 2000-08-03 Jeffrey Thomas Mullaney Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
AU4856600A (en) 1999-05-18 2000-12-05 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
SE9901884D0 (sv) * 1999-05-21 1999-05-21 Pharmacia & Upjohn Ab Novel compounds their use and preparation
ATE313535T1 (de) * 1999-05-21 2006-01-15 Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
NZ516031A (en) 1999-06-15 2003-10-31 Bristol Myers Squibb Pharma Co Substituted heterocycle fused gamma-carbolines
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
US20030004207A1 (en) 1999-11-29 2003-01-02 Douglas A. Craig Use of compounds which activate a 5-ht receptor to treat urinary incontinence
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
AU4316301A (en) 2000-03-14 2001-10-08 Upjohn Co Novel 2,3,4,5-tetrahydro-1H-(1,4)diazepino(1,7a)indole compounds
WO2001083487A1 (fr) 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derive de froindazole
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
JP4204315B2 (ja) * 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
AU2426602A (en) * 2000-11-20 2002-05-27 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
EE200300296A (et) 2000-12-20 2003-12-15 Bristol-Myers Squibb Company Asendatud püridoindoolid kui serotoniini agonistid ja antagonistid ning nende kasutamine
PL366627A1 (en) 2000-12-20 2005-02-07 Bristol-Myers Squibb Company Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
ATE369368T1 (de) 2000-12-27 2007-08-15 Hoffmann La Roche Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
WO2002074746A1 (fr) 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Derives de benzazepine
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
JP2005522407A (ja) 2001-07-05 2005-07-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療用化合物
BR0211559A (pt) 2001-08-06 2004-07-13 Upjohn Co Compostos, composições de ligantes tetracìclicos terapeuticamente úteis e seus usos
ATE306486T1 (de) 2001-08-08 2005-10-15 Pharmacia & Upjohn Co Llc Therapeutische 1h-pyrido(4,3-b)indole
AU2002336749A1 (en) 2001-09-21 2003-04-01 Pharmacia And Upjohn Company Tricyclic indole derivatives as 5-ht ligands
EP1436294A1 (en) * 2001-10-18 2004-07-14 PHARMACIA & UPJOHN COMPANY Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
JP2005516964A (ja) 2001-12-28 2005-06-09 バイエル・フアーマシユーチカルズ・コーポレーシヨン ５−ｈｔ２ｃレセプターと関連する疾患における使用のための１ｈ−ピラゾリル誘導体化合物
AU2002360819A1 (en) 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
WO2003057161A2 (en) 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation BENZOTHIENO [3,2-c]PYRAZOLYL AND BENZOFURANO [3,2-c] PYRAZOLYL COMPOUNDS, THEIR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR AND INTERMEDIATE COMPOUNDS THEREOF
MXPA04005847A (es) 2001-12-28 2004-09-13 Bayer Pharmaceuticals Corp Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
IL165220A0 (en) 2002-06-19 2005-12-18 Biovitrum Ab Novel compounds, their use and preparation

Also Published As

Publication number Publication date
CA2523379C (en) 2010-06-22
KR20100103726A (ko) 2010-09-27
TW200426142A (en) 2004-12-01
MY142857A (en) 2011-01-14
EP2277513A2 (en) 2011-01-26
ZA200507158B (en) 2006-11-29
WO2004096196A2 (en) 2004-11-11
JP2006524679A (ja) 2006-11-02
AU2004233745A1 (en) 2004-11-11
JP2011064695A (ja) 2011-03-31
CL2004000826A1 (es) 2005-03-04
AU2010203093A1 (en) 2010-08-12
WO2004096196A3 (en) 2005-03-10
CN1780612B (zh) 2010-12-01
KR20070108921A (ko) 2007-11-13
CN1780612A (zh) 2006-05-31
EP1620081A2 (en) 2006-02-01
AU2004233745B2 (en) 2010-03-25
KR20060006063A (ko) 2006-01-18
CA2670067A1 (en) 2004-11-11
BRPI0409730A (pt) 2006-05-09
CA2523379A1 (en) 2004-11-11
EP2277513A3 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
MXPA05011410A (es) Tratamiento de incontinencia con agonistas de 5htc2.
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2006044334A3 (en) Platelet-derived growth factor compositions and methods of use thereof
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
BRPI0413305A (pt) compostos azabicìclicos fundidos que inibem o receptor de subtipo de receptor de vanilóide 1 (vr1)
EP1461061A4 (en) COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS
MY127234A (en) Methods for assessing, improving, or maintaining urogenital health in postmenopausal women
AU2003238597A1 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
EP2101772A4 (en) NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS
SG156664A1 (en) Metal ion-containing cmp composition and method for using the same
MXPA03010586A (es) N-[(1s)-1,2,3,4-tertrahidro-1-naftalenil benzamidas trisubtituidas, las cuales inhiben receptores que contienen p2x2/3.
MXPA05007771A (es) Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
AP2003002924A0 (en) 2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulators
SE9904367D0 (sv) Lubricant combination and process for the preparation thereof
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
TNSN03119A1 (en) 5-substituted-2-arylpyridines as crf1 modulators
BR0317229A (pt) Composição e uso de agonista completo de alfa7nachr
IL181991A0 (en) Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
EP1621555A4 (en) IMMUNOGENIC, COMPOSITION FOR IMMUNOLOGICAL USE AND METHOD FOR THE PRODUCTION OF ANTIBODIES WITH THEIR USE
WO2001083714A3 (en) Composition and methods for treating photoreceptor degeneration
DE602005026909D1 (de) Ibopaminmaleat, verfahren zu dessen herstellung und pharmazeutische zusammensetzungen, die dieses enthalten
DE60135773D1 (en) Assays
RU2002103686A (ru) Способ дефосфорации ферромарганца
MX2007013207A (es) Agente para la profilaxis y tratamiento de la pancreatitis.